Meeting
2018 Genitourinary Cancers Symposium
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
Authors
Michaela Ann Dinan
Duke Cancer Institute, Duke University Medical Center, Durham, NC
Michaela Ann Dinan , Mihaela Georgieva , Rahul Shenolikar , Charles D. Scales Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 415)
DOI
10.1200/JCO.2018.36.6_suppl.415
Abstract #
415
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.
First Author: Shilpa Gupta
Poster
2019 ASCO Annual Meeting
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
First Author: Christopher J. Hoimes
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
First Author: Matt D. Galsky